|
Myeloid Neoplasia
Citations 81-90 of 176 total displayed.
|
Past content
(since Jan 2009):
|
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group
- Phoenix A. Ho, Todd A. Alonzo, Robert B. Gerbing, Jessica Pollard, Derek L. Stirewalt, Craig Hurwitz, Nyla A. Heerema, Betsy Hirsch, Susana C. Raimondi, Beverly Lange, Janet L. Franklin, Jerald P. Radich, and Soheil Meshinchi
Blood 2009; 113: 6558-6566.
[Abstract]
[Full text]
[PDF]
Compassionate use of sorafenib in FLT3-ITD–positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation
- Stephan Metzelder, Ying Wang, Ellen Wollmer, Michael Wanzel, Sabine Teichler, Anuhar Chaturvedi, Martin Eilers, Erich Enghofer, Andreas Neubauer, and Andreas Burchert
Blood 2009; 113: 6567-6571.
[Abstract]
[Full text]
[PDF]
How I treat patients with myelodysplastic syndromes
- Richard M. Stone
Blood 2009; 113: 6296-6303.
[Full text]
[PDF]
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy
- Alfonso Quintás-Cardama, Hagop Kantarjian, Dan Jones, Jianqin Shan, Gautam Borthakur, Deborah Thomas, Steven Kornblau, Susan O'Brien, and Jorge Cortes
Blood 2009; 113: 6315-6321.
[Abstract]
[Full text]
[PDF]
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up
- Hagop Kantarjian, Jorge Cortes, Dong-Wook Kim, Pedro Dorlhiac-Llacer, Ricardo Pasquini, John DiPersio, Martin C. Müller, Jerald P. Radich, H. Jean Khoury, Nina Khoroshko, M. Brigid Bradley-Garelik, Chao Zhu, and Martin S. Tallman
Blood 2009; 113: 6322-6329.
[Abstract]
[Full text]
[PDF]
Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms
- Anna M. Jankowska, Hadrian Szpurka, Ramon V. Tiu, Hideki Makishima, Manuel Afable, Jungwon Huh, Christine L. O'Keefe, Rebecca Ganetzky, Michael A. McDevitt, and Jaroslaw P. Maciejewski
Blood 2009; 113: 6403-6410.
[Abstract]
[Full text]
[PDF]
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1
- Ramiro Garzon, Shujun Liu, Muller Fabbri, Zhongfa Liu, Catherine E.A. Heaphy, Elisa Callegari, Sebastian Schwind, Jiuxia Pang, Jianhua Yu, Natarajan Muthusamy, Violaine Havelange, Stefano Volinia, William Blum, Laura J. Rush, Danilo Perrotti, Michael Andreeff, Clara D. Bloomfield, John C. Byrd, Kenneth Chan, Lai-Chu Wu, Carlo M. Croce, and Guido Marcucci
Blood 2009; 113: 6411-6418.
[Abstract]
[Full text]
[PDF]
Therapeutic targeting of MLL
- Michaela Liedtke and Michael L. Cleary
Blood 2009; 113: 6061-6068.
[Abstract]
[Full text]
[PDF]
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms
- Francis H. Grand, Claire E. Hidalgo-Curtis, Thomas Ernst, Katerina Zoi, Christine Zoi, Carolann McGuire, Sebastian Kreil, Amy Jones, Joannah Score, Georgia Metzgeroth, David Oscier, Andrew Hall, Christian Brandts, Hubert Serve, Andreas Reiter, Andrew J. Chase, and Nicholas C. P. Cross
Blood 2009; 113: 6182-6192.
[Abstract]
[Full text]
[PDF]
Identification of AML1-ETO modulators by chemical genomics
- Steven M. Corsello, Giovanni Roti, Kenneth N. Ross, Kwan T. Chow, Ilene Galinsky, Daniel J. DeAngelo, Richard M. Stone, Andrew L. Kung, Todd R. Golub, and Kimberly Stegmaier
Blood 2009; 113: 6193-6205.
[Abstract]
[Full text]
[PDF]
|
|
